Prevalence and Risk Factors Associated with Helicobacter pylori Antibiotic Resistance in Cuenca, Ecuador
DOI:
https://doi.org/10.52787/agl.v54i1.381Keywords:
Helicobacter pylori, antibiotic resistance, antibiotic scheme, antibiogramAbstract
Introduction. Helicobacter pylori is responsible for a highly prevalent bacterial infection in developing countries, and its adequate pharmacological treatment is essential to prevent serious complications such as gastric cancer. However, at present, the usual treatment has significant failure rates, and its main factor is bacterial resistance.
Aim. To identify the frequency and risk factors for resistance to clarithromycin, amoxicillin, azithromycin, metronidazole, and levofloxacin in patients with Helicobacter pylori infection in the Gastroenterology Center, Cuenca, between December 2020 and May 2021.
Material and methods. A single-center observational and descriptive study of 157 adult patients who underwent endoscopic procedures and biopsies that were cultured to obtain resistance rates to different antibiotics. Patients were excluded if they did not sign the informed consent if they had received treatment with antibiotics, bismuth and/or proton pump inhibitors, at least two weeks before the procedure, and if they had received prior treatment for Helicobacter pylori, or with upper gastrointestinal bleeding. Information was collected using a form: age, sex, sociodemographics, and access to public services. Data were presented in tables, with relative frequencies and percentages. Pearson's Chi-square test was used to assess the association between variables. Statistically significant association when p < 0.05.
Results. The prevalence of H. pylori infection was 31.2% by urea test and 12.1% by 48-hour culture. The lowest percentage of resistance was observed for levofloxacin (0%), followed by azithromycin at 16.7%; clarithromycin at 21.1%; amoxicillin 25 mcg at 26.3%; amoxicillin 10 mcg at 31.6% and with the highest percentage of resistance, metronidazole with 63.2%. Resistance to metronidazole and amoxicillin 25 mcg was only significantly associated with patient age, being higher in those older than 60 years.
Conclusions. Metronidazole had a high resistance rate in the sample, while levofloxacin had a sensitivity of 100%. Resistance to metronidazole and amoxicillin 25 mcg was associated with patient longevity.
References
-1. Khoder G, Muhammad JS, Mahmoud I, Soliman SSM, Burucoa C. Prevalence of Helicobacter pylori and Its Associated Factors among Healthy Asymptomatic Residents in the United Arab Emirates. Pathogens. 2019;8(2):44.
-2. Buitrón V, Catalina P. Prevalencia por infección por Helicobacter pylori y asociación con patalogías gástricas en pacientes adultos de chequeo ejecutivo desde enero del 2010 hasta septiembre del 2012 del Hospital Metropolitano de Quito-Ecuador. [Internet] [bachelorThesis]. [Quito, Ecuador]: Universidad San Francisco de Quito; 2013 [citado el 10 de febrero de 2024]. Disponible en: http://repositorio.usfq.edu.ec/handle/23000/1503
-3. Aroca Albiño JM, Vélez Zamora L. Prevalencia de Helicobacter pylori en pacientes asintomáticos en Ecuador. revistavive. 2021;4(11):193-202.
-4. Icaza JDL, Cruz CPV. Prevalencia del Helicobacter pylori mediante antígeno en heces en pacientes sintomáticos del Centro Ambulatorio en Guayaquil-Ecuador. RECIMUNDO. 2019;3(4):78-92.
-5. Cervantes-García E. Helicobacter pylori: mecanismos de patogenicidad. Rev Mex Patol Clin Med Lab. 2016;63(2):100-9.
-6. Marinho JR, Averbach M, Deguti MM, Rodriguez TN. Tratado de Gastroenterologia: da Graduação à Pós-graduação. 2a edição. Zaterka S, Eisig JN, editores. São Paulo: Editora Atheneu; 2016. 1550 p.
-7. Alban O, Medina C, Urquiaga T. Incidencia de resistencia a tratamiento convencional de Helicobacter pylori, en una población adulta de Cajamarca. Revista Caxamarca. 2018;17:103-10.
-8. Reyes Chacón JA, Guzmán Guerrero KV, Pacheco Tigselema RE, Pazmiño Quirós GF, Morales Ñacato EJ, Escalante Vanoni LS. Susceptibilidad antibiótica de Helicobacter pylori: un estudio de prevalencia en pacientes con dispepsia en Quito-Ecuador. Rev Colomb Gastroenterol. 2017;32(4):305-10.
-9. Kouitcheu Mabeku LB, Eyoum Bille B, Tepap Zemnou C, Tali Nguefack LD, Leundji H. Broad spectrum resistance in Helicobacter pylori isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates. BMC Infect Dis. 2019;19(1):880.
-10. Camarena J, Khoury L. Hallazgos recientes de Helicobacter pylori resistente a antibióticos en la República Dominicana. Cienc Salud. 2019;3(3):25-33.
-11. Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;gutjnl-2022-327745.
-12. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of In Frequently Isolated or Fastidious Bacteria. 3er edition. Wayne, PA: Clinical and Laboratory Standards Institute: CLSI guideline M45.;2016.19 p.
-13. Ogata SK, Gales AC, Kawakami E. Antimicrobial susceptibility testing for Helicobacter pylori isolates from Brazilian children and adolescents: comparing agar dilution, E-test, and disk diffusion. Braz J Microbiol. 2014;45(4):1439-48.
-14. Penny Z, Reynolds IS, Buckley M, Martin ST. Rapid urease testing in isolation is inadequate during invasive testing for H. pylori. Ir J Med Sci. 2022;191(2):963-4.
-15. Patel SK, Pratap CB, Jain AK, Gulati AK, Nath G. Diagnosis of Helicobacter pylori: what should be the gold standard? World J Gastroenterol. 2014;20(36):12847-59.
-16. Jearth V, Rath MM, Chatterjee A, Kale A, Panigrahi MK. Drug-Resistant Helicobacter pylori: Diagnosis and Evidence-Based Approach. Diagnostics (Basel). 2023;13(18):2944.
-17. Wang D, Guo Q, Yuan Y, Gong Y. The antibiotic resistance of Helicobacter pylori to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer. BMC Microbiol. 2019;19(1):152.
-18. Almeida N, Romãozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, et al. Helicobacter pylori antimicrobial resistance rates in the central region of Portugal. Clinical Microbiology and Infection. 2014;20(11):1127-33.
-19. Trespalacios AA, Otero Regino W, Mercado Reyes M. Resistencia de Helicobacter pylori a metronidazol, claritromicina y amoxicilina en pacientes colombianos. Revista colombiana de Gastroenterología. 2010;25(1):31-8.
-20. Vallejos M C, Garrido O L, Cáceres L D, Madrid AM, Defilippi C, Defilippi C C, et al. Prevalencia de la resistencia a metrodinazol, claritromicina y tetraciclina en Helicobacter pylori aislado de pacientes de la Región Metropolitana. Rev méd Chile. 2007;135(3):287-93.
-21. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of Primary Resistance of Helicobacter pylori to Metronidazole or Clarithromycin in the United States. Arch Intern Med. 2001;161(9):1217.
-22. Gomollón F, Santolaria S, Sicilia B, Ferrero M, José Revillo M, Ducóns J, et al. Resistencia de Helicobacter pylori al metronidazol y a la claritromicina: análisis descriptivo entre 1997 y 2000. Medicina Clínica. 2004;123(13):481-5.
-23. Gnida A, Felis E, Ziembińska-Buczyńska A, Łuczkiewicz A, Surmacz-Górska J, Olańczuk-Neyman K. Evidence of mutations conferring resistance to clarithromycin in wastewater and activated sludge. 3 Biotech. 2020;10(1):7.
-24. H GZ, Zurita J, Oñate X, Espinosa Y. Patrones de resistencia secundaria de Helicobacter pylori a metronidazol y claritromicina en Quito. Rev Fac Cienc Médicas Quito. 2001;26(2-3):24-75-51.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Esteban González, Diego Cordova Reyes, Paula Abad, Camila González, Juan José Cordero, Eduardo González, Guillermo López Dominguez, Juan Pesantez, Diego Tobar Lima
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
